WO1998037091A3 - Modified retinoblastoma tumor suppressor proteins - Google Patents

Modified retinoblastoma tumor suppressor proteins Download PDF

Info

Publication number
WO1998037091A3
WO1998037091A3 PCT/US1998/003041 US9803041W WO9837091A3 WO 1998037091 A3 WO1998037091 A3 WO 1998037091A3 US 9803041 W US9803041 W US 9803041W WO 9837091 A3 WO9837091 A3 WO 9837091A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor suppressor
retinoblastoma tumor
modified
suppressor proteins
disclosed
Prior art date
Application number
PCT/US1998/003041
Other languages
French (fr)
Other versions
WO1998037091A2 (en
Inventor
Hong-Ji Xu
Shi-Xue Hu
William F Benedict
Yunli Zhou
Original Assignee
Univ Texas
Baylor College Medicine
Xu Hong Ji
Hu Shi Xue
William F Benedict
Yunli Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Baylor College Medicine, Xu Hong Ji, Hu Shi Xue, William F Benedict, Yunli Zhou filed Critical Univ Texas
Priority to IL13149698A priority Critical patent/IL131496A0/en
Priority to AU66573/98A priority patent/AU6657398A/en
Priority to CA002281899A priority patent/CA2281899A1/en
Priority to EP98908570A priority patent/EP0975750A2/en
Priority to JP53678898A priority patent/JP2001512325A/en
Publication of WO1998037091A2 publication Critical patent/WO1998037091A2/en
Publication of WO1998037091A3 publication Critical patent/WO1998037091A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Disclosed are modified broad-spectrum retinoblastoma tumor suppressor proteins that have at least the same, and in most cases higher biological activity than the corresponding wild-type retinoblastoma tumor suppressor protein. Exemplary modified retinoblastoma tumor suppressor proteins have a modified N-terminal region, in particular comprising one or more deletions and/or mutations. Also disclosed are methods of making and using the modified retinoblastoma tumor suppressor proteins, particularly in circumstances where inhibition of cell growth is desired. Thus the present disclosure provides methods for treating diseases, as exemplified by, but not limited to cancer, that are characterized by abnormal cellular proliferation.
PCT/US1998/003041 1997-02-20 1998-02-19 Modified retinoblastoma tumor suppressor proteins WO1998037091A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IL13149698A IL131496A0 (en) 1997-02-20 1998-02-19 Modified retinoblastoma tumor suppressor proteins
AU66573/98A AU6657398A (en) 1997-02-20 1998-02-19 Modified retinoblastoma tumor suppressor proteins
CA002281899A CA2281899A1 (en) 1997-02-20 1998-02-19 Modified retinoblastoma tumor suppressor proteins
EP98908570A EP0975750A2 (en) 1997-02-20 1998-02-19 Modified retinoblastoma tumor suppressor proteins
JP53678898A JP2001512325A (en) 1997-02-20 1998-02-19 Modified retinoblastoma tumor suppressor protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3811897P 1997-02-20 1997-02-20
US60/038,118 1997-02-20

Publications (2)

Publication Number Publication Date
WO1998037091A2 WO1998037091A2 (en) 1998-08-27
WO1998037091A3 true WO1998037091A3 (en) 1998-11-05

Family

ID=21898180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/003041 WO1998037091A2 (en) 1997-02-20 1998-02-19 Modified retinoblastoma tumor suppressor proteins

Country Status (8)

Country Link
EP (1) EP0975750A2 (en)
JP (1) JP2001512325A (en)
KR (1) KR20000075501A (en)
CN (1) CN1259998A (en)
AU (1) AU6657398A (en)
CA (1) CA2281899A1 (en)
IL (1) IL131496A0 (en)
WO (1) WO1998037091A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110484623A (en) * 2019-08-27 2019-11-22 深圳市宝安区妇幼保健院 A kind of RB1 mutated gene, primer, detection method, kit and application
US11597757B2 (en) 2019-09-27 2023-03-07 Saint Leo University Peptide for treating cancer
WO2023173105A2 (en) * 2022-03-10 2023-09-14 Saliogen Therapeutics, Inc. Tetracycline inducer/repressor system and simplified viral particle production

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021115A1 (en) * 1993-03-25 1994-09-29 Baylor College Of Medicine Broad spectrum tumor suppressor genes, gene products and methods for tumor suppression gene therapy
WO1995007708A2 (en) * 1993-09-13 1995-03-23 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
WO1996020207A1 (en) * 1994-12-23 1996-07-04 Research Development Foundation MUTANTS OF THE Rb AND p53 GENES AND USES THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021115A1 (en) * 1993-03-25 1994-09-29 Baylor College Of Medicine Broad spectrum tumor suppressor genes, gene products and methods for tumor suppression gene therapy
WO1995007708A2 (en) * 1993-09-13 1995-03-23 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
WO1996020207A1 (en) * 1994-12-23 1996-07-04 Research Development Foundation MUTANTS OF THE Rb AND p53 GENES AND USES THEREOF

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANTELMAN D. ET AL.: "Engineered mutants of pRB with improved growth suppression potential.", ONCOGENE, vol. 15, no. 23, 4 December 1997 (1997-12-04), pages 2855 - 66, XP002075615 *
HIEBERT S W: "REGIONS OF THE RETINOBLASTOMA GENE PRODUCT REQUIRED FOR ITS INTERACTION WITH THE E2F TRANSCRIPTION FACTOR ARE NECESSARY FOR E2 PROMOTER REPRESSION AND PRB-MEDIATED GROWTH SUPPRESSION", MOLECULAR AND CELLULAR BIOLOGY, vol. 13, no. 6, June 1993 (1993-06-01), pages 3384 - 3391, XP000615601 *
HONG-JI XU ET AL: "ENHANCED TUMOR CELL GROWTH SUPPRESSION BY AN N-TERMINAL TRUNCATED RETINOBLASTOMA PROTEIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, October 1994 (1994-10-01), pages 9837 - 9841, XP002029760 *
QIAN Y ET AL: "BIOLOGICAL FUNCTION OF THE RETINOBLASTOMA PROTEIN REQUIRES DISTINCT DOMAINS FOR HYPERPHOSPHORYLATION AND TRANSCRIPTION FACTOR BINDING", MOLECULAR AND CELLULAR BIOLOGY, vol. 12, no. 12, December 1992 (1992-12-01), pages 5363 - 5372, XP000615356 *
QIN X -Q ET AL: "IDENTIFICATION OF GROWTH SUPPRESSION DOMAIN WITHIN THE RETINOBLASTOMA GENE PRODUCT", GENES AND DEVELOPMENT, vol. 6, no. 6, June 1992 (1992-06-01), pages 953 - 964, XP000676628 *
ZHOU, Y. ET AL.: "Mechanisms for the enhanced tumor cell growth suppression by an N-terminal truncated RB protein.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH - 87TH ANNUAL MEETING, vol. 37, March 1996 (1996-03-01), pages 595 - 6, XP002075614 *

Also Published As

Publication number Publication date
AU6657398A (en) 1998-09-09
EP0975750A2 (en) 2000-02-02
CN1259998A (en) 2000-07-12
KR20000075501A (en) 2000-12-15
JP2001512325A (en) 2001-08-21
CA2281899A1 (en) 1998-08-27
IL131496A0 (en) 2001-01-28
WO1998037091A2 (en) 1998-08-27

Similar Documents

Publication Publication Date Title
CA2291892A1 (en) Angiostatin fragments and method of use
PL331240A1 (en) Cut off soluble tumour necrosis factor receptors of i and ii type
MY125594A (en) Immortalized cell lines for virus growth
AU3847997A (en) Inhibitors of the interaction between P53 and MDM2
PL329922A1 (en) Quinoline carboxamides as inhibitors of the tumour necrosis factor and of phosphodiesterase
CA2219081A1 (en) Angiostatin fragments and aggregate angiostatin and methods of use
GR3036188T3 (en) Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
WO1999036553A3 (en) Regulation of biological events using multimeric chimeric proteins
AU3111700A (en) Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity
WO2000009553A3 (en) Antimicrobial peptides isolated from the skin of american frogs
WO1999042596A3 (en) Phosphodiesterase 10
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
WO1997031116A3 (en) Recombinant ribonuclease proteins
IL124015A0 (en) Pharmaceutical compositions comprising a protein
BG102280A (en) Peptides of antisecretory factor regulating the pathological permeability alterations
WO2003026580A3 (en) Interactive therapeutic enclosures
WO1998037091A3 (en) Modified retinoblastoma tumor suppressor proteins
EP0921194A3 (en) TRAILLK-2: a member of the TNF ligand family
EP0919620A3 (en) TRAILLK-3: a member of the TNF ligand family
WO2002083892A3 (en) Mutants of desoxycytidine kinase having extended enzymatic activity
DE69837808D1 (en) pRb2 / p130 PEPTIDINHIBITORS OF cdk2 KINASEACTIVITY
IL128546A0 (en) Cycloalkyl inhibitors of protein farnesyltransferase
WO1995007708A3 (en) Therapeutic use of the retinoblastoma susceptibility gene product
WO2000044391A3 (en) Plasminogen kringle 4 region fragments and methods of use
WO1999019481A3 (en) Mammalian genes involved in viral infection and tumor suppression

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 131496

Country of ref document: IL

Ref document number: 98802742.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2281899

Country of ref document: CA

Ref document number: 2281899

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1998 536788

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997007560

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 66573/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998908570

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998908570

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997007560

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1998908570

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998908570

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997007560

Country of ref document: KR